Astarte Medical awarded support to help advance microbiome-based human health solutions
BOSTON, November 1, 2017 (Newswire.com) - Astarte Medical Partners won first place at the Bugs, Drugs & Beyond: Translational Approaches to the Microbiome Quickfire Challenge sponsored by Johnson & Johnson Innovation, JLABS (JLABS), and the Janssen Human Microbiome Institute (JHMI), part of Janssen Research & Development, LLC.
Astarte Medical is developing NICUtritionTM, a software platform to optimize feeding and nutrition and quantify gut health for preterm infants. Astarte Medical was selected to compete against five other companies at the one-day microbiome event in Boston. As the winner, Astarte Medical will receive a cash award along with a customized support package, including coaching, from JHMI and JLABS.
Companies were evaluated based on the potential to impact healthcare outcomes, uniqueness of their solution, quality and feasibility of the technology, team credibility and capabilities, and clarity of milestones.
This event had 250 attendees which undoubtedly included the top minds in microbiome science. We are thrilled to receive a monetary award but as importantly, close collaboration with experts from the Janssen Human Microbiome Institute and Johnson & Johnson Innovation.
“This event had 250 attendees which undoubtedly included the top minds in microbiome science,” said Astarte Medical CEO, Tracy Warren. “We are thrilled to receive a monetary award but as importantly, close collaboration with experts from the Janssen Human Microbiome Institute and Johnson & Johnson Innovation.”
Astarte Medical, based in Yardley, PA, is the first microbial health informatics company. NICUtritionTM will revolutionize the care of preterm infants by quantifying gut health and standardizing care resulting in lower costs and better outcomes, both in the short- and long-term.
Source: Astarte Medical Partners